Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALY II Japan: MB-CART2019.1 in R/R DLBCL
NCT07288879Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Dec 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of zamtocabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Objective Response Rate at 1 month. Started Dec 2025; status: recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07288879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288879.